SCHEMBL18909535

SCHEMBL18909535

CCOC(=O)c1ccc(C(C)(C)CC)s1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.56
HPGD P15428 4/20 0.56
L3MBTL1 Q9Y468 3/20 0.56
MAPK1 P28482 1/20 0.56
ATM Q13315 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
HDAC3 O15379 1/20 0.56
HDAC4 P56524 1/20 0.56
HDAC1 Q13547 1/20 0.56
HDAC6 Q9UBN7 1/20 0.56
LMNA P02545 1/20 0.42
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
CDC7 O00311 1/20 0.41
DBF4 Q9UBU7 1/20 0.41
ERN1 O75460 2/20 0.40
GAA P10253 2/20 0.39
MAPT P10636 2/20 0.39
CA12 O43570 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12514085 0.87 HDAC3 (0.59) TSHRHPGDL3MBTL1MAPK1ATM
SCHEMBL3333355 0.85 HDAC3 (0.58) TSHRHPGDL3MBTL1MAPK1ATM
SCHEMBL16423406 0.84 HDAC4 (0.65) TSHRHPGDL3MBTL1MAPK1ATM
SCHEMBL7018973 0.80 HDAC3 (0.73) TSHRHPGDL3MBTL1HDAC3HDAC4
SCHEMBL27782216 0.80 DAO (0.61) TSHRHPGDL3MBTL1MAPK1ATM
SCHEMBL13462527 0.80 LMNA (0.67) TSHRHPGDL3MBTL1MAPK1ATM
SCHEMBL19892225 0.78 HDAC4 (0.61) TSHRHPGDL3MBTL1MAPK1ATM
SCHEMBL21303399 0.78 HDAC4 (0.61) TSHRHPGDL3MBTL1MAPK1ATM
SCHEMBL4429773 0.76 HDAC3 (0.51) TSHRHPGDL3MBTL1MAPK1ATM
SCHEMBL4432493 0.76 HDAC3 (0.51) TSHRHPGDL3MBTL1MAPK1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9981901-B2 IRE-1α inhibitors FOSUN ORINOVE PHARMATECH, INC. (CN) 2018-05-29 US disclosed
US-20170152206-A1 IRE-1alpha INHIBITORS FOSUN ORINOVE PHARMATECH, INC. (CN) 2017-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170152206-A1 IRE-1alpha INHIBITORS XBP1, DDIT3, ERN1 TSHR 3005/4885HPGD 1032/4885L3MBTL1 784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.